Cases & Deals

Cellectis completes acquisition of Cellartis and €50 million private placement and issues free share purchase warrants to existing shareholders

Client(s) Cellectis SA

Jones Day advised Cellectis SA, a world leader in genome engineering listed on the Alternext market of NYSE Euronext Paris, in connection with the €33.8 million acquisition of Cellartis, the European stem cell leader, in conjunction with the €50 million private placement of convertible bonds evenly subscribed by the Fonds Stratégique d'Investissement (FSI) and Pierre Bastid and the issuance of free share purchase warrants to existing shareholders.